0.24
+0.97%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Elite Pharmaceuticals
From its filings with the US Securities and Exchange Commission
Elite Pharmaceuticals is based in Northvale, New Jersey and is incorporated in New Jersey. Its shares trade on OTC under the ticker ELTP. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 March 2026, it reported revenue of $148.9m and net income of $44.9m. At that date it held total assets of $138.3m and shareholders' equity of $98.9m.
Act of 1984 (the “Drug Price Competition Act”) as well as generic drug products which require ANDAs.
35mg is currently a commercial product being manufactured at the Northvale Facility and distributed by Elite Labs.
Agreement expired in accordance with its terms on September 10, 2025. The Company retains all sales and marketing rights for this product.
15mg and Phentermine 30mg are currently commercial products being manufactured at the Northvale Facility and distributed by Elite Labs.
50mg is currently a commercial product being manufactured at the Northvale Facility and distributed by Elite Labs.
2.5mg and Isradipine 5mg are commercial products being manufactured by Elite at the Northvale Facility and distributed by Elite Labs.
IR Tablets are currently a commercial product being manufactured by Elite and distributed by Elite Labs.
Codeine Tablets were commercially launched in October 2024 and are manufactured at the Northvale Facility and distributed by Elite Labs.
APAP Tablets were commercially launched in April 2025 and are manufactured at the Northvale Facility and distributed by Elite Labs.
Quoted from its 10-K, filed 29 Jun 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 23 Jul 1998
- Employees
- 65
- Website
- elitepharma.com ↗
- Head office
- 165 LUDLOW AVENUE, NORTHVALE, NJ, 07647
- Incorporated in
- NJ
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Nasrat HakimChairman of the Board, President, Chief Executive Officer, since 2013$1.1m
- Mr. Carter WardChief Financial Officer, Treasurer, Secretary$413,187
- Mr. Douglas PlasscheExecutive Vice President - Operations$526,718
- Mr. Kirko KirkovChief Commercial Officer$216,913
- Mr. Davis CaskeyIndependent Director$30,000
- Dr. Barry DashIndependent Director$30,000
- Mr. Jeffrey WhitnellIndependent Director$30,000
- Ms. Dianne WillInvestor Relations Officer
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 6
- Environment
- 4
- Social
- 11
- Governance
- 3
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Elite Pharmaceuticals Inc possesses several strengths that contribute to its competitiveness and success in the pharmaceutical industry. These include:
Weaknesses
- Despite its strengths, Elite Pharmaceuticals Inc also faces certain weaknesses that could pose challenges to its growth and profitability. These weaknesses include:
Opportunities
- Elite Pharmaceuticals Inc can capitalize on various opportunities to further grow and expand its business. These opportunities include:
Threats
- Elite Pharmaceuticals Inc faces certain threats that may hinder its growth and profitability. These threats include:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.